Article info
PDFTherapeutics/Prevention
Cost effectiveness study
Cardiac resynchronisation therapy with an implantable cardioverter defibrillator appears to be cost-effective in patients with mild heart failure
- Correspondence to : Dr Keith Cooper, University of Southampton, SHTAC, Epsilon House, Enterprise Road, Southampton, SO16 7NS, UK; kc{at}soton.ac.uk
Citation
Cardiac resynchronisation therapy with an implantable cardioverter defibrillator appears to be cost-effective in patients with mild heart failure
Publication history
- First published February 17, 2016.
Online issue publication
February 14, 2020
Article Versions
- Previous version (14 February 2020).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/